Background. Human immunodeficiency virus type 1 (HIV-1) gp41 is a crucial determinant for HIV-1 pathogenicity. We investigated the correlation of enfuvirtide (ENF)-associated gp41 mutational clusters with viroimmunological parameters, as well as the potential underlying mechanisms.
(asparagine-X-serine/threonine) for the incorporation of N-linked carbohydrates; their presence acts to decrease the portion of gp41 surface that serves as an immunogenic target.
Enfuvirtide (marketed as T-20 or Fuzeon) is the first fusion inhibitor approved for clinical practice. It interacts with HR1, preventing the formation of the 6-helix bundle, and consequently, the fusion process. To date, 18 mutations at 8 positions in the "enfuvirtide (ENF) target region" that encompass amino acids 36 -45 of HR1 have been associated with ENF-resistance [3] [4] [5] [6] [7] [8] .
There is increasing evidence that additional mutations outside the ENF target region are involved in ENF resistance, and therefore lead to virological failure in patients who receive ENF therapy. For instance, recent studies have proposed that some additional mutations in HR2 contribute to ENF resistance, but their exact role still remains unclear [9 -11] .
Another relevant point that has not been still elucidated is the impact of ENF-resistance mutations on HIV-1 fitness and/or cytopathic effect. HIV-1 gp41 has been demonstrated to be a crucial determinant of HIV-1 pathogenicity, given its involvement in mechanisms that trigger the apoptosis of CD4 ϩ T cells [12] [13] [14] [15] [16] [17] . Interestingly, some gp41 mutations that are able to impair gp41 fusogenicity have been demonstrated to reduce the ability of HIV-1 to induce apoptosis in CD4 ϩ T cells without interfering with viral replication capacity [17, 18] . In this context, it is conceivable that ENF pressure may be associated with mutations that modulate the cytopathic effects of HIV-1 by mechanisms that are not necessarily related to viral replication capacity. On the basis of these assumptions, we analyzed the full-length gp41 sequences and viroimmunological parameters with the aim of clarifying the gp41 mutational pathways associated with ENF treatment and their correlation with viroimmunological outcome.
METHODS

Study population.
The study included 73 nonselected, highly treatment-experienced patients infected with HIV-1 B-subtype who had a history of multiple virological failures, followed up in 3 major centers in Italy. To make the data more clear and readable from the genetic point of view, patients who carried HIV-1 non-B subtypes have been excluded from this analysis. For most patients, ENF was added as a single active drug to the last failing regimen. For 20 patients, minor regimen modifications (i.e., changes limited to a single nucleoside reverse transcriptase inhibitor [NRTI] or to a single protease inhibitor [PI] in the context of extensive multidrug resistance) were made at the time that ENF therapy was started. Of 73 patients, 62 (85.3%) received ENF together with 1-3 NRTIs and at least 1 PI. Only 11 patients received nonnucleoside reverse transcriptase inhibitors (NNRTIs) with ENF due to the high prevalence at baseline of mutations that conferred full resistance to this class of drugs. For each patient, the level of viremia and CD4 ϩ cell count were monitored every month during ENF treatment. A total of 172 plasma samples were obtained from 73 patients at the time of virological failure and at different time points later during treatment with ENF. Baseline samples from 49 (67.1%) of 73 patients were also available for gp41 sequencing. As a control, 38 other patients infected with HIV-1 who had not received treatment with ENF were included in the analysis of gp41 mutations. Gp41 sequencing. The sequencing of the entire gp41 was performed on plasma samples, as described elsewhere [19] . In brief, RNA was extracted, retrotranscribed, and amplified by use of 2 different sequence-specific primers. Gp41-amplified products were full-length sequenced in sense and antisense orientations by use of 8 different overlapping sequencespecific primers for an automated sequencer (ABI 3100; Applied Biosystems). Sequences with a mixture of wild-type and mutant residues at single positions were considered to have the mutant(s) at that position. Nucleotide sequences were submitted to Genbank (accession number: EU251192-EU251378 and EU281662-EU281733). Subtypes were assessed by the construction of phylogenetic trees generated with the Kimura 2-parameter model. The statistical robustness within each phylogenetic tree was confirmed with a bootstrap analysis using 1000 replicates.
Statistical analysis of mutation prevalence. To assess the association of gp41 mutations with ENF treatment, we calculated the frequency of all mutations in the 345 gp41 residues in isolates from 87 ENF-naive patients (11 were completely naive to antiretroviral drugs and 76 had been treated with highly active antiretroviral therapy; 49 were later treated with ENF) and in isolates from 73 patients who experienced virological failure while receiving ENF (virological failure was defined as viremia of Ͼ400 copies/mL in 2 consecutive tests). Fisher exact tests were used to determine whether the differences in frequency between the 2 groups of patients were statistically significant. For patients who had more than one gp41 sequence available during ENF treatment, the sequence obtained most recently during the treatment period was analyzed.
To assess the association of specific ENF-associated mutational clusters with changes in the level of viremia and CD4 ϩ cell count, we compared the mean change in the level of viremia and CD4 ϩ cell count from baseline to week 48 for the subset of patients who had viral isolates with a specific ENF-associated mutational cluster and the subset of patients who had viral isolates without such a cluster. Mann-Whitney U tests were used to assess statistically significant differences. All statistical tests were corrected for multiple hypothesis testing by using BenjaminiHochberg method at a false discovery rate (FDR) of 0.05 [20] .
Statistical analysis of mutation covariation. For the 73 ENF-treated patients, we analyzed patterns of interactions among selected mutations associated with ENF treatment, including novel mutations. The details of this explorative data analysis procedure have been described elsewhere [21, 22] . In brief, for each pair of mutations and corresponding wild-type residues, the Fisher exact test was performed to assess whether co-occurrence of the mutated residues differed significantly from what would be expected under an independence assumption. The Benjamini-Hochberg method was used to correct for multiple testing at an FDR of 0.05 [20] . Samples having a mixture of 2 or more mutations at a given pair of positions were ignored in calculating the covariation, due to the impossibility of identifying whether these mutations were located in the same viral genome. To identify higher-order interactions of mutations, we transformed the pairwise correlation coefficients into dissimilarity values. Based on these pairwise dissimilarity values, a dendrogram was computed by hierarchical clustering. To assess the stability of the resulting dendrogram, confidence values for all subtrees in the dendrogram were computed by 500 replicates of the clustering procedure on sequence sets bootstrapped from the original 73 sequences.
Genotypic sensitivity. We used resistance testing information to calculate a genotypic sensitivity score (GSS) [23] . The GSS was calculated by using the Stanford HIV Drug Resistance Database sequence analysis program [24] .
Structural analysis. The x-ray crystallographic coordinates of HIV-1 gp41 deposited in the Protein Data Bank [25] with code 1IF3 were used for the structural analysis. From this model, the mutants were generated by single-residue replacement in all chains. Energy-minimized starting structures were subjected to molecular dynamic simulations (MDSs) under the following conditions: (1) 1.5 picoseconds of equilibration time at 300K; (2) 1000 picoseconds of simulation time at 300K; (3) time-step, 1.5 femtoseconds; (4) 200 conformations stored; (5) AMBER* force field [26] and (6) GibbsBorn surface area water implicit model, to take into account the solvation effect. All simulations were performed by MacroModel (version 7.2; Schrödinger) [27] . To evaluate the most important interactions at interface of the HR1 and HR2 subdomains, the programs LigPlot and DimPlot (open-source software) [28] were used to select the most-involved gp41 residues. All molecular dynamics conformations were analyzed by adopting a distance based descriptor that computed the Boltzmann probability at 300K. Six dummy atoms that averaged all the atoms of the residues 38 and 140 for each chain were generated, and their distances with respect to residue N145 [29 -31] were measured. All three-dimensional figures were created using the PyMOL Molecular Graphics System (PyMOL). Table 1 summarizes the demographic and clinical characteristics of the 73 ENF-treated patients. All patients were heavily treatment-experienced, with resistance to multiple NRTIs, NNRTIs, and PIs. They were experiencing virological failure in response to their last antiretroviral regimen, with the level of viremia stable at about 5 log 10 copies/mL and CD4 Gp41 mutations in patients who experienced virological failure during ENF therapy. The classic ENF-resistance mutations were observed in 68 (93.1%) of 73 ENF-treated patients who experienced virological failure. Among them, the frequency of G36D/V, V38A/E, Q39H, Q40H, N42T, N43D, L44M, and L45M showed a significant increase in isolates recovered from ENF-treated patients, compared with isolates recovered from ENF-naive patients (P ϭ .05 to Ͻ.001) (figure 1A). Beyond the classic ENF-resistance mutations, we identified 7 other gp41 mutations that were significantly associated with ENF treatment (P Ͻ .05) (figure 1B). In particular, T18A/P, N126K, and D239H occurred at a frequency of 2.2%, 1.1%, and 3.4%, respectively, in isolates from ENF-naive patients; they increased to frequencies of 12.3%, 16.4%, and 15.1%, respectively, in isolates from ENF-treated patients (P ϭ .01 to .001). The other novel gp41 mutations (S129D, N140I, and T268A) were already present in isolates from ENF-naive patients at frequencies of 13.8%, 9.2%, 34.5%, respectively, which increased after ENF treatment to 28.8%, 21.9%, 52.0% (P ϭ .02, in all 3 cases) (figure 1B) . No other gp41 mutations showed a statistically significant increase in frequency among ENF-treated patients.
RESULTS
Patient characteristics.
Associations among gp41 mutations. Some novel gp41 mutations were positively correlated into pairs with the classic ENF-resistance mutations (P Ͻ .05) (table 2). In particular, the most frequently selected ENF-resistance mutation, V38A, was strongly correlated with the novel mutations T18A (, 0.41) and N140I (, 0.16). T18A never occurred without the presence of V38A. V38A was negatively correlated with the classic ENFresistance mutations N43D (, Ϫ0.25), Q40H (, Ϫ0.23), and L45M (, Ϫ0.22). In contrast, the classic ENF-resistance mutations Q40H and L45M were strongly correlated with each other (, 0.93) and with the novel D239H mutation (, 0.22), whereas Figure 1 . Frequency of the classic (A) and novel (B) gp41 mutations significantly associated with virological failure in patients who received enfuvirtide (ENF). The frequency of mutations was calculated in isolates from 87 ENF-naive patients and 73 patients who experienced virological failure to ENF. Statistically significant differences were assessed by Fisher exact tests. P values were significant at a false discovery rate of .05 after correction for multiple comparison. *, P Ͻ .05; **, P Ͻ .01; ***, P Ͻ .001.
G36V was significantly associated with the novel mutation N126K (, 0.36).
Clusters of correlated mutations. The topology of the dendrogram (figure 2) suggests the existence of at least 5 distinct clusters of mutations that involve both novel and classic ENFresistance mutations. In particular, a strong cluster was formed by the classic ENF-resistance mutations Q40H and L45M to which the novel mutations D239H and T268A were linked as well. In contrast, V38A and G36V clustered with the novel mutations T18A ϩ N140I and N126K, respectively (figure 2).
Association of ENF-resistance mutations with viroimmunological outcome among ENF-treated patients. By investi- gating the correlation of ENF-resistance mutations with viroimmunological parameters, we found that the viroimmunological outcome for ENF-treated patients varied remarkably according to which gp41 mutational pathways occurred during ENF treatment. We observed that the presence of mutations V38A ϩ T18A or V38A ϩ N140I was significantly associated with a sharp and sustained increase of CD4 ϩ cell count, despite the maintenance of virological failure. Specifically, the mean change in CD4 ϩ cell count from baseline to week 48 in the presence of V38A ϩ T18A or V38A ϩ N140I was 112 cells/L and 209 cells/L, respectively (figure 3A). These changes were 6.7-fold and 20.7-fold higher than those observed in the absence of such ϩ cell count at week 48 between patients with V38A ϩ N140I or V38A ϩ T18A and patients without mutations at positions 18, 38, and 140. P values in italics indicate a statistically significant difference in the mean change of CD4 ϩ cell count at week 48 between patients with V38A ϩ N140I or V38A ϩ T18A and patients with V38A alone. Mean changes in the level of viremia were not statistically significant (P Ͼ .8). B, P value indicates a statistically significant difference in the mean change in CD4 ϩ cell count at week 48 between patients with N126K and patients without mutations at position 126. Mean changes in the level of viremia were not statistically significant (P ϭ .9). C, P value indicates a statistically significant difference in the mean change in CD4 ϩ cell count at week 48 between patients with Q40H ϩ L45M ϩ T268A and patients without mutations at positions 40, 45, and 268. The mean change in CD4 ϩ cell count in presence of Q40H ϩ L45M (without T268A) was similar to that observed without mutations at position 40, 45, and 268, and it was not reported because the pair Q40H ϩ L45M (without T268A) was present in only 2 patients. Mean changes in the level of viremia were not statistically significant (P ϭ .9). All P values remained significant after correction for multiple hypothesis testing [20] , with the exception of the P values reported in italics. WT, wild type. mutations (P ϭ .01 and P ϭ .03, respectively), and 1.5-fold and 4.5-fold higher than those observed in the presence of V38A alone (P ϭ .02 and P ϭ .04, respectively) (figure 3A). V38A ϩ T18A or V38A ϩ N140I were not associated with any significant changes in the level of viremia from baseline to week 48 (0.27 and Ϫ0.15 log 10 copies/mL, in the presence of V38A ϩ T18A and V38A ϩ N140I, respectively), or when compared with viral changes observed in the absence of these mutations (Ϫ0.30 log 10 copies/mL) or in the presence of V38A alone (Ϫ0.23 log 10 copies/mL) (P Ͼ .8). Similarly, the presence of N126K was associated with a mean change of CD4 ϩ cell count from baseline to week 48 that was 5-fold higher than that observed in the absence of this mutation (154 vs. Ϫ7.5 cells/L; P ϭ .012), without any significant effect on the level of viremia (Ϫ0.11 log 10 copies/mL in the presence of N126K vs. Ϫ0.50 log 10 copies/mL in the absence of N126K; P ϭ .8) ( figure 3B ). Such increases in CD4 ϩ cell count are not related to residual efficacy of the drugs administered together with ENF or to an accumulation of mutations in the protease (PR) and reverse transcriptase (RT) genes in HIV-1. Indeed, the median GSS were very similar (ranging from a median value of 0.35 to 0.38), and the median increase in the number of PR and RT mutations after 48 weeks was 0 (IQR, 0 -1) and 1 (IQR, 0 -1), respectively, in patients with the different patterns of mutations. In contrast, the other ENF-associated cluster-Q40H ϩ L45M ϩ T 268 A-was significantly correlated with a decrease in CD4 ϩ cell count at week 48 (Ϫ53 cells/L in the presence of this cluster vs. 94 cells/L in the absence of this cluster; P ϭ .04) ( figure  3C ), but (again) without significant changes in the level of viremia (Ϫ0.22 log 10 copies/mL vs. Ϫ0.63 log 10 copies/mL; P ϭ .9).
MDS. The stability of the 6-helix bundle requires hydrophobic interactions between specific HR1 and HR2 residues in each hairpin [29 -31] (figure 4A). One of them is just residue 38, which establishes Van der Waals interaction with residue 145 ( figure 4A) . By performing MDS, we investigated the impact of mutations at position 38 and 140 on the formation of this important interaction, by monitoring for 1 nanosecond, every 5 picoseconds (for a total of 201 observations), the distance and the frequency of occurrence of the Van der Waals interaction between residues 38 and 145 (figure 4B). Our MDS showed that in the presence of V38A ϩ N140I, the distance between the residues 38A and 145N was increased in all 3 hairpins (Ͼ6.5Å) (table 3) . This, in turn, significantly reduced the frequency of occurrence of the Van der Waals interaction in all the 3 hairpins (P Ͻ .001). Thus, in presence of V38A ϩ N140I the interaction between residues 38 and 145, which is important for the formation of the 6-helix bundle, is drastically impaired.
DISCUSSION
This study, which involved one of the largest cohorts of ENFtreated patients assembled thus far, shows that ENF pressure is associated with intriguing patterns of gp41 mutations that significantly correlate with an increase or decrease in CD4 ϩ cell count, without any significant correlation with the level of viremia. This suggests the potential involvement of gp41's structure in the modulation of HIV-1-induced damage to the immune system, by mechanisms not necessarily related to viral replication capacity. In this context, our findings represent an interesting concept with potential relevance for the design of the next generation of entry inhibitors.
In particular, we found that the patterns of mutations V38A ϩ T18A and V38A ϩ N140I were associated with a significant increase in CD4 ϩ cell count, despite full virological failure. The V38A mutation has recently been shown to be associated with an increase in CD4 ϩ cell count, even in presence of ongoing viral replication, in different independent data sets, including that from the ENF phase 3 clinical trials [19, 32] . In this study, we found that the increase in CD4 ϩ cell count associated with V38A is strongly and significantly reinforced by the concomitant presence of T18A or N140I. Because this is one of the most interesting (and clinically relevant) phenomena related to ENF treatment, we analyzed our data and others' data to find potential explanations of this result.
We first excluded the possibility that V38A, N140I, and T18A confer changes in known HLA-restricted cytotoxic T lymphocyte gp41 epitopes [33] . In addition, a recent study demonstrated that the V38A mutation does not increase the sensitivity of gp41 to the neutralizing antibodies 2F5 and 4E10 [34] . Thus, these findings suggest that the increase in CD4 ϩ cell count induced by V38A ϩ T18A or N140I is not directly associated with cytotoxic T lymphocyte responses and/or neutralizing antibodies, but is instead related to completely different and peculiar mechanisms.
By performing MDS, we observed that, in presence of V38A ϩ N140I, the interaction between the gp41 residues 38 and 145 that is important for the stabilization of the 6-helix bundle [29 -31] is drastically impaired. Thus, one might hypothesize that the abrogation of this interaction might reduce the gp41 fusogenic activity at a level sufficient to affect the induction of CD4 ϩ T cell apoptosis but insufficient to affect fusion with the host cell. This model might explain why, in the presence of V38A ϩ N140I, we observed a significant increase in CD4 ϩ cell count but not a significant decrease in the level of viremia.
The mechanism of interaction for V38A and N140I at the protein level seems not to apply to the cluster V38A ϩ T18A, thus we explored the reason(s) of the coevolution of these 2 latter mutations by analyzing the nucleotidic sequence of gp41. Interestingly, T18A-and V38A-corresponding nucleotides are located complementarily to each other in the stem IIA of the Rev-responsive element (RRE). This stem has been shown to participate in the Rev interaction [35] [36] [37] , thus promoting the stability and transport of unspliced and partially spliced HIV-1 mRNAs out of the nucleus, a step that is essen-tial for the HIV-1 life cycle. V38A and T18A each derive from a nucleotide substitution, GUG to GCG, and ACU to GCU, respectively. The release of free energy observed with the mutated base pair C:G is even higher than that observed with the wild-type base-pair U:A (⌬G, Ϫ3.4 Kcal/mol vs. ⌬G, Ϫ2.1 Kcal/mol) [38] . In addition, the copresence of T18A (GCU) and V38A (GCG) is associated with a higher level of viremia at virological failure. Overall findings suggest that these mutations, when copresent, may contribute to stabilize the secondary structure of the RRE, to influence the Rev-RRE interaction, and thus to potentially increase the replication capacity of HIV-1. Our hypothesis is consistent with the results of a previous study that demonstrated that the amino acid mutation I37T in the gp41 protein corresponds to a nucleotide change in the RRE, which impairs the stability of this RNA element. It has been suggested that the mutations A30V and G36D may appear in the gp41 protein as a consequent readjustment of the secondary structure of the RRE, and thus rescue RRE stability [37] . These findings suggest that changes in the nucleotide sequence of the RRE, induced by the ENF pressure, may alter its conformation and the Rev-RRE interaction. Thus, they highlight the importance of the correct interplay between the different HIV-1 genes and proteins during the HIV-1 life cycle and the ability of ENF (and of entry inhibitors in general) to modulate the viral life cycle at different steps at both the protein and RNA levels simultaneously.
Similarly, N126K was also associated with a significant increase in CD4 ϩ cell count, despite virological failure. This in- Figure 4 . A, Residues in HR1 and HR2 whose interaction is critical for the formation and stabilization of the 6-helix bundle. In the picture, the residues in HR1 and HR2 involved in the formation and stabilization of the 6-helix bundle are reported in bold type [29 -31] . Lines, interaction between these residues. Residues 38 and 145 are in bold type. B, Insight of the gp41 6-helix bundle showing the distance between residues 38 and 145 in the wild-type gp41 protein and in presence of V38A Ϯ N140I. Side chains of residues 38, 140, and 145 are highlighted in wire-frame. Each hairpin is represented by a different color.
crease might be related to the ability of the N126K mutation to abrogate the fourth gp41 N-linked glycosylation site, thus potentially resulting in the exposure of a previously hidden immunogenic epitope.
Unlike the previous gp41 mutational patterns, the ENFassociated cluster Q40H ϩ L45M ϩ T268A is significantly associated with a decrease in CD4 ϩ cell count. Interestingly, the novel mutation T268A is located within the lentivirus lyticpeptide 2 (LLP2) domain, which plays a key role in the modulation of HIV-1 cytopathic effect. In particular, it has been demonstrated that deletions in the LLP2 domain result in a more fusogenic virus able to induce the apoptosis of CD4 ϩϩ T lymphocytes more efficiently [39] . In addition, it has been shown that LLP2 directly interacts with calmodulin, thus triggering the Fas-mediated apoptosis of CD4 ϩ T lymphocytes [12, 40] . Although further in vitro studies are necessary, it is conceivable that the presence of the T268A mutation alone or together with the resistance mutations Q40H ϩ L45M might enhance the cytopathic properties of gp41. This hypothesis is supported by a recent study showing that mutations in the LLP2 domain represent important determinants for the acquisition of the cytopathic phenotype by CCR5-using HIV-1 strains at late stages of disease progression [41] .
Because the early virological response has previously been demonstrated to predict the immunological response [42, 43] , we have determined virological responses at week 8 and week 12 in the subsets of patients with V38A, V38A ϩ T18A, V38A ϩ N140I, N126K, and Q40H ϩ L45M ϩ T268A, and we have verified that virological responses are similar and not significantly different in the 5 groups of patients (P Ͼ .5; data not shown). Thus, differences in the mean changes in level of viremia at early time points seem not to be related to the increase in CD4 ϩ cell count in the presence of specific mutational patterns. This supports the hypothesis that the increase in CD4 ϩ cell count associated with specific gp41 mutational patterns has no direct relationship to decreases in the level of viremia under ENF treatment. We need to emphasize that the proposed mechanisms of action of gp41 mutations are models that require validation by in vitro experiments. In addition, it should be pointed out that our data were derived under a "worst case scenario" situation, that is, under clinical conditions in which ENF was added as single active drug. Thus, it is possible that the specific mutations and the clusters of mutations that we observed under these conditions might not be recapitulated among patients who received several active agents simultaneously.
In conclusion, our study shows that ENF pressure can be associated with specific patterns of mutations that correlate with an increase or decrease in CD4 ϩ cell count, without any significant correlation with the level of viremia. The models proposed to explain the mechanisms of action of these mutational patterns suggest that they may alter the Rev-RRE interactions, decrease HIV-1 cytopathic effect, and/or enhance immune response by mechanisms that may operate even under conditions of virological failure. Of course, further analyses of enlarged databases (that include genotypic and clinical data), complemented by experimental validation will provide insights regarding the hypotheses formulated and may lead to an improved understanding of the impact of these mutations on HIV-1 pathogenicity. Confirmation of these hypotheses may support the correct positioning of ENF in therapy for HIV-infected patients and may represent an attractive driving force for the design of the next generation entry inhibitors.
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